Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. (Q36848183)

16 August 2017

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. (English)

1 reference

16 August 2017

1 reference

6

Frits van Rhee

0 references

Bart Barlogie

9

object named as

Bart Barlogie

1 reference

16 August 2017

4

Elias Anaissie

1 reference

16 August 2017

2

Maurizio Zangari

1 reference

16 August 2017

Mauricio Pineda-Roman

1

1 reference

16 August 2017

Jeff Haessler

3

1 reference

16 August 2017

Guido Tricot

5

1 reference

16 August 2017

John Crowley

7

1 reference

16 August 2017

John D Shaughnessy

8

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 March 2008

1 reference

British Journal of Haematology

16 August 2017

1 reference

16 August 2017

140

1 reference

16 August 2017

6

1 reference

16 August 2017

625-634

1 reference

The molecular classification of multiple myeloma

16 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3655432

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3655432

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3655432

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3655432

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3655432

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3655432

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3655432

Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3655432

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3655432

Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3655432

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3655432

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3655432

Single versus double autologous stem-cell transplantation for multiple myeloma.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3655432

Nonparametric Estimation from Incomplete Observations

5 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06921.X

Treatment of multiple myeloma

21 January 2018

1 reference

12 December 2020

Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3

1 reference

12 December 2020

Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma

1 reference

12 December 2020

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

1 reference

12 December 2020

Cytogenetic findings in 200 patients with multiple myeloma

1 reference

12 December 2020

Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol

1 reference

12 December 2020

10.1111/J.1365-2141.2007.06921.X

Identifiers

DOI

1 reference

16 August 2017

1 reference

16 August 2017

PubMed publication ID

18302711

1 reference